AAP
AKCA

Ardsley Advisory Partners’s Akcea Therapeutics Inc AKCA Stock Holding History

Ardsley Advisory Partners’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,000
Closed -$260K – 186
2017
Q4 		$260K Buy
15,000
+5,000
+50% +$98K 0.03% 121
2017
Q3 		$277K Buy
+10,000
New +$185K 0.04% 114

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ardsley Advisory Partners's AKCA Position: Q1 2018 in Review

Ardsley Advisory Partners sold out of Akcea Therapeutics Inc (AKCA) in Q1 2018, closing a stake of 15,000 shares — an estimated $260K sold.

Ardsley Advisory Partners first reported a position in AKCA in Q3 2017 and held it in 2 quarters. The position peaked at $277K in Q3 2017. 57 funds tracked by Wall St. Rank hold AKCA as of Q1 2018.

  • Ardsley Advisory Partners reported no remaining Akcea Therapeutics Inc position as of Q1 2018 after selling out during the quarter.
  • Ardsley Advisory Partners sold 15,000 Akcea Therapeutics Inc shares in Q1 2018, an estimated $260K.
  • Ardsley Advisory Partners first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 2 quarters.
  • Ardsley Advisory Partners's Akcea Therapeutics Inc position peaked at $277K in Q3 2017.
  • 57 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2018.

Based on Ardsley Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.